(CPHI) China Pharma Holdings - Ratings and Ratios

Exchange: NYSE MKT • Country: China • Currency: USD • Type: Common Stock • ISIN: US16941T1043

CPHI: Injectables, Tablets, Capsules, Sanitizers

China Pharma Holdings, Inc. (NYSE MKT: CPHI) is a specialty pharmaceutical company focused on developing, manufacturing, and distributing generic and branded pharmaceutical, biochemical, and healthcare products in the Peoples Republic of China. The company specializes in producing injectables, tablets, capsules, and oral solutions targeting cardiovascular, cerebrovascular, and neurological conditions, among others. Its product portfolio includes treatments for memory decline, cerebral thrombosis, hypertension, and infectious diseases, as well as supplements and personal protective equipment (PPE) such as sanitizers and masks.

The company operates through a network of distributors, sales offices, and representatives, ensuring broad access to its products across China. Its offerings include prescription drugs, over-the-counter medications, and health supplements, addressing a wide range of medical needs. With a market capitalization of $3.69 million and a price-to-book ratio of 0.68, the stock is currently trading at $0.23, with a 20-day average volume of 590,214 shares. The 20-day, 50-day, and 200-day moving averages are aligned at $0.22 and $0.23, respectively, indicating stable price action. The average true range (ATR) of $0.03 reflects low volatility.

3-Month Forecast: Based on , the stock is expected to remain range-bound between $0.20 and $0.25, with minimal upside potential due to low volatility and a flat moving average trend. The suggests limited growth prospects, as indicated by a negative return on equity (-72.67%) and a low price-to-sales ratio (0.80). However, the companys focus on essential healthcare products may provide near-term stability. Investors should monitor for potential catalysts, such as new product approvals or strategic partnerships, to drive upward momentum.

Additional Sources for CPHI Stock

CPHI Stock Overview

Market Cap in USD 4m
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
GiC Sub-Industry Pharmaceuticals
IPO / Inception 2002-04-17

CPHI Stock Ratings

Growth 5y -91.8%
Fundamental -32.5%
Dividend 0.0%
Rel. Strength Industry -32.6
Analysts -
Fair Price Momentum 0.14 USD
Fair Price DCF -

CPHI Dividends

No Dividends Paid

CPHI Growth Ratios

Growth Correlation 3m 47.7%
Growth Correlation 12m -68.9%
Growth Correlation 5y -92.1%
CAGR 5y -60.77%
CAGR/Max DD 5y -0.61
Sharpe Ratio 12m -0.12
Alpha -42.70
Beta 1.00
Volatility 174.16%
Current Volume 443.6k
Average Volume 20d 653k
What is the price of CPHI stocks?
As of March 15, 2025, the stock is trading at USD 0.24 with a total of 443,649 shares traded.
Over the past week, the price has changed by +6.36%, over one month by +13.10%, over three months by +47.17% and over the past year by -32.01%.
Is China Pharma Holdings a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, China Pharma Holdings (NYSE MKT:CPHI) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -32.48 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CPHI as of March 2025 is 0.14. This means that CPHI is currently overvalued and has a potential downside of -41.67%.
Is CPHI a buy, sell or hold?
China Pharma Holdings has no consensus analysts rating.
What are the forecast for CPHI stock price target?
According to ValueRays Forecast Model, CPHI China Pharma Holdings will be worth about 0.2 in March 2026. The stock is currently trading at 0.24. This means that the stock has a potential downside of -37.5%.
Issuer Forecast Upside
Wallstreet Target Price 3 1150%
Analysts Target Price - -
ValueRay Target Price 0.2 -37.5%